Mitochondrial DNA Release from Senescent Immune Cells Drives Systemic Aging via cGAS-STING Activation in Stromal Niches

Hypothesis

Senescent immune cells actively release mitochondrial DNA (mtDNA) into the extracellular space, where it acts as a damage‑associated molecular pattern (DAMP) that triggers the cGAS‑STING pathway in stromal cells, leading to chronic type‑I interferon signaling and amplification of the senescence‑associated secretory phenotype (SASP). This mechanism positions mitochondrial DAMPs from the immune system as a primary driver of systemic aging, rather than a mere by‑product of immune decline.

Mechanistic Basis

1. mtDNA release – Senescent T cells and macrophages exhibit mitochondrial dysfunction and increased mitochondrial permeability, allowing mtDNA to escape into the cytosol and be packaged into extracellular vesicles (EVs) 2.
2. DAMP signaling – Extracellular mtDNA binds cytosolic cGAS in stromal fibroblasts and epithelial cells, activating STING‑dependent IRF3 phosphorylation and IFN‑β production 3.
3. SASP amplification – IFN‑β signaling induces STAT1‑mediated transcription of IL‑6, IL‑1β, and MMPs, creating a paracrine loop that reinforces immune cell senescence and tissue damage 4.
4. Feedback to hematopoietic stem cells – Chronic IFN exposure skews hematopoiesis toward myeloid lineages, further increasing the pool of senescent innate cells 5.

Thus, the immune system does not merely fail to clear senescent neighbors; it actively generates a mitochondrial DAMP signal that reprograms the stromal microenvironment to sustain aging.

Testable Predictions

• Prediction 1: Young mice receiving senescent immune cells pre‑treated with a mitochondrial antioxidant (e.g., MitoQ) will show lower tissue cGAS‑STING activation, reduced SASP markers, and delayed onset of age‑related phenotypes compared with mice receiving untreated senescent immune cells.
• Prediction 2: Genetic deletion of cGAS specifically in stromal fibroblasts will abolish the pro‑aging effects of transplanted senescent immune cells, even when mtDNA release is intact.
• Prediction 3: Pharmacological inhibition of STING in aged mice will attenuate the systemic inflammation normally driven by aged immune transplants, improving grip strength and treadmill endurance.

Each prediction yields clear, falsifiable outcomes: measurable changes in IFN‑β levels, p‑STING immunostaining, senescence‑associated β‑galactosidase activity, and functional assays.

Potential Interventions

• Target mtDNA packaging in senescent immune cells using inhibitors of vesicular trafficking (e.g., GW4869) to block EV release.
• Enhance mitochondrial quality control in hematopoietic stem cells with urolithin A or NAD⁺ boosters to reduce mtDNA leakage.
• Administer STING antagonists (e.g., H‑151) intermittently to break the IFN‑SASP loop without compromising acute antiviral immunity.

By focusing on the mitochondrial DAMP axis, we shift from broadly suppressing immunity to precisely neutralizing the immune‑derived signal that fuels systemic aging.

References (inline)

• Dysfunctional mitochondria in T cells accelerate aging 2
• Senescent T cells express NK receptors causing tissue damage 3
• Aged macrophages lose phagocytic capacity 4
• HSC myeloid skewing amplifies inflammation 5
• Transplantation of aged immune cells induces senescence 1
• Transient senescence aids regeneration 6